Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mobile Mindfulness Meditation Intervention to Improve the Well-Being of Cancer Survivors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03581357
Recruitment Status : Recruiting
First Posted : July 10, 2018
Last Update Posted : September 28, 2021
Sponsor:
Collaborator:
VA Palo Alto Health Care System
Information provided by (Responsible Party):
University of Hawaii

Brief Summary:
Evaluate the impact and satisfaction of Mobile Mindfulness Meditation on anxiety, pain, fatigue, trauma, and sleep in cancer survivors.

Condition or disease Intervention/treatment Phase
Cancer, Other Than Non-melanoma Skin Cancer Behavioral: Mobile Mindfulness Meditation Behavioral: Mindfulness Coach Not Applicable

Detailed Description:

Through previous research, mindfulness meditation has been linked to decreases in anxiety, increased pain tolerance, better mood, and improved quality of life, in both healthy and medical populations. Although mindfulness meditation is well promoted both clinically and in the media, finding ways to promote engagement in and fidelity to the intervention, in a format that is accessible for cancer survivors is crucial, as the availability of resources and appreciation of the benefits does not necessarily lead to behavior change.

With many more people surviving cancer than in previous decades, there is an opportunity to act on the residual effects of cancer diagnosis and treatment, and with the prevalence of technology ever increasing, online and mobile interventions have become more frequently delivered and have a particular utility for this population. Physical and geographic limitations could prevent cancer survivors from accessing psychosocial interventions. Whether the repeated beneficial findings of face-to-face training in mindfulness meditation will be found in a mobile environment is an open and timely question. This intervention will include two arms: the impact of the use of the mobile app for anxiety and for cancer related neuropathy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This study will be conducted as a randomized wait-list control design, such that participants will be randomized to either begin the intervention immediately or after 8 weeks.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Mobile Mindfulness Meditation Intervention to Improve the Well-Being of Cancer Survivors
Actual Study Start Date : April 3, 2019
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Control/Waitlist (Anxiety Group)
Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
Behavioral: Mobile Mindfulness Meditation
It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.

Active Comparator: Mindfulness App (Anxiety Group)
Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
Behavioral: Mobile Mindfulness Meditation
It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.

Active Comparator: Control/Waitlist (Neuropathy Group)
Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
Behavioral: Mindfulness Coach
It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.

Active Comparator: Mindfulness App (Neuropathy Group)
Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
Behavioral: Mindfulness Coach
It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.




Primary Outcome Measures :
  1. Evaluate the impact of Mobile Mindful Meditation on anxiety as measured with the GAD-7 (Anxiety Arm) [ Time Frame: 8 weeks ]
    Anxiety will be measured with the GAD-7, which entails respondents indicating how much in the past week they experienced anxiety. Participants are asked to provide their responses on a 5-point Likert type scale, with options ranging from "never" to "always."

  2. Evaluate the impact of Mobile Mindful Meditation on pain as measured with the PEG-3 (Anxiety Arm) [ Time Frame: 8 weeks ]
    Pain will be measured with the PEG-3, a three item measure assessing pain intensity, interference with general activity, and interference with enjoyment of life, with response options ranging from a 0-10 scale (0 being "no pain" or "does not interfere" and 10 being "pains as bad as you can imagine" or "completely interferes").

  3. Evaluate the impact of Mobile Mindful Meditation on fatigue as measured with the Brief Fatigue Inventory (Anxiety Arm) [ Time Frame: 8 weeks ]
    Fatigue will be measured with the Brief Fatigue Inventory, a 9-item measure where respondents are asked to rate their fatigue on an 11-point scale, with options on three items ranging from either "no fatigue" to "as bad as you can imagine" and options on the remaining items ranging from "does not interfere" to "completely interferes"

  4. Evaluate the impact of Mobile Mindful Meditation on trauma as measured with the PCL-5 (Anxiety Arm) [ Time Frame: 8 weeks ]
    Trauma Symptoms will be measured with the PCL-5. This 20-item measure assess for the 20 DSM-5 symptoms of PTSD, which fit into the larger categories of intrusive and avoidant symptoms.

  5. Evaluate the impact of Mobile Mindful Meditation on sleep as measured by the PROMIS sleep scale (Anxiety Arm) [ Time Frame: 8 weeks ]
    Sleep will be measured by the PROMIS sleep scale, an 8-item measure, with 5-point response choices.

  6. Evaluate the impact of Mindfulness Coach on pain as measured with the McGill Pain Questionnaire (Neuropathy Arm) [ Time Frame: 8 weeks ]
    This is a self-report questionnaire, consisting of 3 major classes of word descriptors--sensory, affective/emotional impact and cognitive evaluation of pain. The Short-form McGill Pain Questionnaire (SFMPQ) was developed to provide an instrument that could be completed in less time than the MPQ but would still reflect both the sensory and affective dimensions of pain and has been shown to have high correlations with the original McGill Pain Scale.

  7. Evaluate the impact of Mindfulness Coach on anxiety as measured with the PROMIS anxiety (Neuropathy Arm) [ Time Frame: Baseline, 8 weeks, 16 weeks ]
    This is a 22 item measure created for cancer survivors to measure both symptoms of anxiety and whether help was needed due to anxiety symptoms65. This is included at all time-points as an additional outcome measure.

  8. Evaluate the impact of Mindfulness Coach on fatigue as measured with the BFI (Neuropathy Arm) [ Time Frame: Baseline, 8 weeks, 16 weeks ]
    The Brief Fatigue Inventory (BFI) is a 15-item measure assessing both the severity of fatigue and the impact of fatigue on daily functioning64. This is included at all three time-points as an additional outcome measure.

  9. Evaluate the impact of Mindfulness Coach on Quality of Life as measured with the FACT scale (Neuropathy Arm) [ Time Frame: Baseline, 8 weeks, 16 weeks ]
    The FACT-GOC-Ntx scale includes 11 additional items (27 original items and 11 CIPN items) to measure the severity and impact of chemotherapy induced peripheral neuropathy. This data will serve as both a screening tool and baseline measure of CIPN.


Secondary Outcome Measures :
  1. Evaluate the satisfaction with Mobile Mindfulness Meditation as measured by questionnaires on the Online Mindful Meditation platforms (Anxiety Arm) [ Time Frame: Baseline, 16 weeks ]
    Patient self-reporting through the Mobile Mindful Meditation platform will measure satisfaction via the Five Facet Mindfulness Questionnaire. Successfully completing the 8-week program will also be an indirect measure of patient satisfaction.

  2. Evaluate the satisfaction with Mindfulness Coach [ Time Frame: Baseline, 16 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Anxiety Arm:

  1. previous diagnosis of cancer, other than non-melanoma skin cancer
  2. over 21 years of age
  3. routine access to the Internet
  4. comfortable reading and writing in English
  5. have completed primary treatment for cancer
  6. indicate the presence of cancer related anxiety as indicated by the PROMIS measure
  7. not currently practicing meditation regularly (more than one hour per week), and
  8. diagnosed with any stage of cancer
  9. own a smartphone or tablet

Cancer Related Neuropathy Arm

  1. diagnosis of cancer
  2. use of a taxane or platinum agent
  3. experiencing CIPN, per self-report
  4. over 21 years of age
  5. routine access to a smart device
  6. comfortable reading and writing in English, and
  7. not currently practicing meditation regularly (more than one hour per week).

Exclusion Criteria:

None


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03581357


Contacts
Layout table for location contacts
Contact: Erin O Bantum, PhD 808-441-3491 ebantum@cc.hawaii.edu

Locations
Layout table for location information
United States, California
Palo Alto VA Health Care System Recruiting
Palo Alto, California, United States, 94304
United States, Hawaii
University of Hawaii Cancer Center Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Erin O Bantum, Ph.D.    808-441-3491    ebantum@cc.hawaii.edu   
Principal Investigator: Erin O Bantum, Ph.D.         
Sponsors and Collaborators
University of Hawaii
VA Palo Alto Health Care System
Investigators
Layout table for investigator information
Principal Investigator: Erin O Bantum, PhD University of Hawaii Cancer Research Center
Layout table for additonal information
Responsible Party: University of Hawaii
ClinicalTrials.gov Identifier: NCT03581357    
Other Study ID Numbers: Bantum-2017-1
First Posted: July 10, 2018    Key Record Dates
Last Update Posted: September 28, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Hawaii:
Previous diagnosis of cancer, completed primary treatment of cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Neoplasms
Neoplasms by Site
Neoplasms
Skin Diseases